Abstract

In 2004, the government of Mexico established the National Institute of Genomic Medicine (INMEGEN), to carry out disease-related genomic studies that will address national health problems and stimulate scientific and technological development by generating new commercial products and services in genomic medicine. Towards this end, INMEGEN is carrying out a large-scale genotyping project to map genomic variation within its own population. The initiative is expected to generate a key resource for local researchers to understand disease susceptibility and variation in drug responses, which will contribute to Mexico's goal of developing public health genomics — a field in which Mexico is proving to be a leader amongst emerging economies.

Author affiliations

1. Billie-Jo Hardy, Béatrice Séguin, Peter A. Singer and Abdallah S. Daar are at the McLaughlin–Rotman Centre for Global Health, Program on Life Sciences, Ethics and Policy, University Health Network and University of Toronto, MaRS Centre, South Tower, Suite 406, 101 College Street, Toronto, Ontario M5G 1L7, Canada.
2. Béatrice Séguin is also at the Leslie Dan Faculty of Pharmacy, University of Toronto, 144 College Street, Toronto, Ontario M5S 3M2, Canada.
3. Peter A. Singer and Abdallah S. Daar are also at the McLaughlin Centre for Molecular Medicine, MaRS Centre, Toronto Medical Discovery Tower, Suite 701, 101 College Street, Toronto, Ontario M5G 1L7, Canada.

Correspondence to: Abdallah S. Daar³ Email: a.daar@utoronto.ca

MORE ARTICLES LIKE THIS

These links to content published by NPG are automatically generated.